Subscribe | Docwire News
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care professionals.
Sign up for DocWire News eNewsletters to get the latest medical industry news and expert insights and to join an extensive community of health care professionals.
The pivotal phase 3 INTerpath-009 trial has begun global recruitment of patients with resectable non-small cell lung cancer, according to Merck and Moderna.
Stay informed with latest cancer breakthroughs, treatments, updates from leading hematology oncology experts. Insights from top cancer conferences and podcasts.
Drs. Finn and Yopp discuss the IMbrave050 study for early-stage HCC, including the trial design, results, and implications.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Questions surrounding informed consent, mandatory versus optional biopsy, and safety for adults and children are addressed.
As a busy GP and mum, Anisha relies on fresh fruit and high-protein foods like eggs to get her through the day
The European Commission (EC) has approved zolbetuximab (Vyloytm) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment.
“Heart disease has been known as a degenerate disease that is synonymous with the elderly. But it is currently showing an alarming trend, because this…
Using an accelerated course of radiation therapy ādoes not increase complicationsā in patients who undergo breast reconstruction after a mastectomy.
The four-year grant is for $2.5 million and will fund a project titled, āImmune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.ā